# Repligen Corp: financial statements, quarterly

RGEN · Nasdaq · CIK 730272 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rgen.md) · [Financials](/companies/rgen/financials.md) · [Filings](/companies/rgen/filings.md) · [Insiders](/companies/rgen/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rgen/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [141](/filings/0000950170-24-127846.md) | [167 d](/filings/0001193125-26-076528.md) | [153](/filings/0000950170-25-060156.md) | [159](/filings/0000950170-25-105166.md) | [155](/filings/0001193125-25-264666.md) | [168 d](/filings/0001193125-26-076528.md) | [169](/filings/0001193125-26-208954.md) | [182](/filings/0001193125-26-323773.md) | [189](/filings/0001193125-25-264666.md) | [198 d](/filings/0001193125-26-076528.md) | [194](/filings/0001193125-26-208954.md) | [204](/filings/0001193125-26-323773.md) |
| Cost of revenue | $m | [105](/filings/0000950170-24-127846.md) | [88.1 d](/filings/0001193125-26-076528.md) | [76.4](/filings/0000950170-25-060156.md) | [77.3](/filings/0000950170-25-105166.md) | [77.4](/filings/0001193125-25-264666.md) | [129 d](/filings/0001193125-26-076528.md) | [77.8](/filings/0001193125-26-208954.md) | [89.4](/filings/0001193125-26-323773.md) | [88.3](/filings/0001193125-25-264666.md) | [94.1 d](/filings/0001193125-26-076528.md) | [86.0](/filings/0001193125-26-208954.md) | [94.1](/filings/0001193125-26-323773.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [10.6](/filings/0000950170-24-127846.md) | [10.3 d](/filings/0001193125-26-076528.md) | [11.2](/filings/0000950170-25-060156.md) | [10.6](/filings/0000950170-25-105166.md) | [9.7](/filings/0001193125-25-264666.md) | [11.7 d](/filings/0001193125-26-076528.md) | [12.1](/filings/0001193125-26-208954.md) | [14.0](/filings/0001193125-26-323773.md) | [14.2](/filings/0001193125-25-264666.md) | [13.1 d](/filings/0001193125-26-076528.md) | [14.5](/filings/0001193125-26-208954.md) | [14.4](/filings/0001193125-26-323773.md) |
| Selling, general and administrative | $m | [55.6](/filings/0000950170-24-127846.md) | [57.6 d](/filings/0001193125-26-076528.md) | [61.8](/filings/0000950170-25-060156.md) | [65.5](/filings/0000950170-25-105166.md) | [75.6](/filings/0001193125-25-264666.md) | [60.5 d](/filings/0001193125-26-076528.md) | [70.7](/filings/0001193125-26-208954.md) | [70.9](/filings/0001193125-26-323773.md) | [73.7](/filings/0001193125-25-264666.md) | [74.4 d](/filings/0001193125-26-076528.md) | [76.5](/filings/0001193125-26-208954.md) | [76.6](/filings/0001193125-26-323773.md) |
| Operating income | $m | [4.7](/filings/0000950170-24-127846.md) | [9.9 d](/filings/0001193125-26-076528.md) | [3.8](/filings/0000950170-25-060156.md) | [5.5](/filings/0000950170-25-105166.md) | [(7.8)](/filings/0001193125-25-264666.md) | [(36.5) d](/filings/0001193125-26-076528.md) | [6.6](/filings/0001193125-26-208954.md) | [13.9](/filings/0001193125-26-323773.md) | [16.8](/filings/0001193125-25-264666.md) | [17.9 d](/filings/0001193125-26-076528.md) | [15.9](/filings/0001193125-26-208954.md) | [14.0](/filings/0001193125-26-323773.md) |
| Interest expense | $m | [0.3](/filings/0000950170-23-056871.md) | [1.1 d](/filings/0000950170-24-018809.md) | [4.9](/filings/0000950170-24-051310.md) | [5.0](/filings/0000950170-24-087981.md) | [5.1](/filings/0001193125-25-264666.md) | [5.5 d](/filings/0001193125-26-076528.md) | [5.3](/filings/0001193125-26-208954.md) | [5.4](/filings/0001193125-26-323773.md) | [5.4](/filings/0001193125-25-264666.md) | [5.5 d](/filings/0001193125-26-076528.md) | [5.6](/filings/0001193125-26-208954.md) | [5.7](/filings/0001193125-26-323773.md) |
| Income tax | $m | [(5.5)](/filings/0000950170-24-127846.md) | [18.3 d](/filings/0001193125-26-076528.md) | [0.4](/filings/0000950170-25-060156.md) | [3.3](/filings/0000950170-25-105166.md) | [(0.5)](/filings/0001193125-25-264666.md) | [(4.7) d](/filings/0001193125-26-076528.md) | [2.1](/filings/0001193125-26-208954.md) | [3.3](/filings/0001193125-26-323773.md) | [2.2](/filings/0001193125-25-264666.md) | [5.8 d](/filings/0001193125-26-076528.md) | [(6.6)](/filings/0001193125-26-208954.md) | [9.1](/filings/0001193125-26-323773.md) |
| Net income | $m | [16.9](/filings/0000950170-24-127846.md) | [(16.5) d](/filings/0001193125-26-076528.md) | [3.3](/filings/0000950170-25-060156.md) | [5.7](/filings/0000950170-25-105166.md) | [(0.7)](/filings/0001193125-25-264666.md) | [(33.9) d](/filings/0001193125-26-076528.md) | [5.8](/filings/0001193125-26-208954.md) | [14.9](/filings/0001193125-26-323773.md) | [14.9](/filings/0001193125-25-264666.md) | [13.3 d](/filings/0001193125-26-076528.md) | [8.3](/filings/0001193125-26-208954.md) | [5.0](/filings/0001193125-26-323773.md) |
| Diluted EPS | $ per share | [0.30](/filings/0000950170-24-127846.md) | not reported | [0.06](/filings/0000950170-25-060156.md) | [0.10](/filings/0000950170-25-105166.md) | [(0.01)](/filings/0001193125-25-264666.md) | not reported | [0.10](/filings/0001193125-26-208954.md) | [0.26](/filings/0001193125-26-323773.md) | [0.26](/filings/0001193125-25-264666.md) | not reported | [0.15](/filings/0001193125-26-208954.md) | [0.09](/filings/0001193125-26-323773.md) |
| Basic EPS | $ per share | [0.30](/filings/0000950170-24-127846.md) | not reported | [0.06](/filings/0000950170-25-060156.md) | [0.10](/filings/0000950170-25-105166.md) | [(0.01)](/filings/0001193125-25-264666.md) | not reported | [0.10](/filings/0001193125-26-208954.md) | [0.26](/filings/0001193125-26-323773.md) | [0.27](/filings/0001193125-25-264666.md) | not reported | [0.15](/filings/0001193125-26-208954.md) | [0.09](/filings/0001193125-26-323773.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [631](/filings/0000950170-24-127841.md) | [751](/filings/0000950170-25-038999.md) | [781](/filings/0000950170-24-127844.md) | [809](/filings/0000950170-24-127845.md) | [784](/filings/0000950170-24-127846.md) | [757](/filings/0001193125-26-076528.md) | [697](/filings/0001193125-26-208954.md) | [709](/filings/0001193125-26-323773.md) | [749](/filings/0001193125-25-264666.md) | [566](/filings/0001193125-26-323773.md) | [583](/filings/0001193125-26-208954.md) | [607](/filings/0001193125-26-323773.md) |
| Current assets | $m | [980](/filings/0000950170-24-127841.md) | [1,111](/filings/0000950170-25-038999.md) | [1,131](/filings/0000950170-24-127844.md) | [1,157](/filings/0000950170-24-127845.md) | [1,132](/filings/0000950170-24-127846.md) | [1,066](/filings/0001193125-26-076528.md) | [1,032](/filings/0000950170-25-060156.md) | [1,057](/filings/0000950170-25-105166.md) | [1,096](/filings/0001193125-25-264666.md) | [1,137](/filings/0001193125-26-323773.md) | [1,161](/filings/0001193125-26-208954.md) | [1,201](/filings/0001193125-26-323773.md) |
| Total assets | $m | [2,523](/filings/0000950170-24-127841.md) | [2,831](/filings/0000950170-25-038999.md) | [2,854](/filings/0000950170-24-127844.md) | [2,866](/filings/0000950170-24-127845.md) | [2,831](/filings/0000950170-24-127846.md) | [2,830](/filings/0001193125-26-076528.md) | [2,852](/filings/0000950170-25-060156.md) | [2,902](/filings/0000950170-25-105166.md) | [2,924](/filings/0001193125-25-264666.md) | [2,950](/filings/0001193125-26-323773.md) | [2,931](/filings/0001193125-26-208954.md) | [2,950](/filings/0001193125-26-323773.md) |
| Current liabilities | $m | [379](/filings/0000950170-24-127841.md) | [165](/filings/0000950170-25-038999.md) | [182](/filings/0000950170-24-127844.md) | [175](/filings/0000950170-24-127845.md) | [108](/filings/0000950170-24-127846.md) | [127](/filings/0001193125-26-076528.md) | [152](/filings/0000950170-25-060156.md) | [123](/filings/0000950170-25-105166.md) | [131](/filings/0001193125-25-264666.md) | [136](/filings/0001193125-26-323773.md) | [126](/filings/0001193125-26-208954.md) | [133](/filings/0001193125-26-323773.md) |
| Total liabilities | $m | [549](/filings/0000950170-24-127841.md) | [866](/filings/0000950170-25-038999.md) | [888](/filings/0000950170-24-127844.md) | [882](/filings/0000950170-24-127845.md) | [814](/filings/0000950170-24-127846.md) | [857](/filings/0001193125-26-076528.md) | [867](/filings/0000950170-25-060156.md) | [840](/filings/0000950170-25-105166.md) | [841](/filings/0001193125-25-264666.md) | [844](/filings/0001193125-26-323773.md) | [825](/filings/0001193125-26-208954.md) | [838](/filings/0001193125-26-323773.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [526](/filings/0001193125-26-076528.md) | not reported | not reported | [538](/filings/0001193125-25-264666.md) | [542](/filings/0001193125-26-323773.md) | [547](/filings/0001193125-26-208954.md) | [551](/filings/0001193125-26-323773.md) |
| Shareholders' equity | $m | [1,974](/filings/0000950170-24-127846.md) | [1,965](/filings/0001193125-26-076528.md) | [1,966](/filings/0000950170-25-105166.md) | [1,984](/filings/0001193125-25-264666.md) | [2,017](/filings/0001193125-25-264666.md) | [1,973](/filings/0001193125-26-323773.md) | [1,985](/filings/0001193125-26-323773.md) | [2,062](/filings/0001193125-26-323773.md) | [2,083](/filings/0001193125-25-264666.md) | [2,106](/filings/0001193125-26-323773.md) | [2,105](/filings/0001193125-26-323773.md) | [2,112](/filings/0001193125-26-323773.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [39.2 d](/filings/0000950170-24-127846.md) | [29.1 d](/filings/0001193125-26-076528.md) | [44.7](/filings/0000950170-25-060156.md) | [42.2 d](/filings/0000950170-25-105166.md) | [49.3 d](/filings/0001193125-25-264666.md) | [39.2 d](/filings/0001193125-26-076528.md) | [15.0](/filings/0001193125-26-208954.md) | [28.6 d](/filings/0001193125-26-323773.md) | [48.1 d](/filings/0001193125-25-264666.md) | [25.7 d](/filings/0001193125-26-076528.md) | [28.3](/filings/0001193125-26-208954.md) | [32.8 d](/filings/0001193125-26-323773.md) |
| Capital expenditure | $m | [8.4 d](/filings/0000950170-24-127846.md) | [11.1 d](/filings/0001193125-26-076528.md) | [8.3](/filings/0000950170-25-060156.md) | [4.8 d](/filings/0000950170-25-105166.md) | [7.0 d](/filings/0001193125-25-264666.md) | [5.5 d](/filings/0001193125-26-076528.md) | [3.6](/filings/0001193125-26-208954.md) | [7.1 d](/filings/0001193125-26-323773.md) | [4.7 d](/filings/0001193125-25-264666.md) | [8.2 d](/filings/0001193125-26-076528.md) | [4.7](/filings/0001193125-26-208954.md) | [5.3 d](/filings/0001193125-26-323773.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.1](/filings/0000950170-24-127841.md) | [0.1](/filings/0000950170-24-127844.md) | [0.1](/filings/0000950170-24-127845.md) | [0.1](/filings/0000950170-24-127846.md) | [0.1](/filings/0000950170-25-060156.md) | [0.1](/filings/0000950170-25-105166.md) | [0.1](/filings/0001193125-25-264666.md) | [56.6](/filings/0001193125-26-208954.md) | [56.5](/filings/0001193125-26-323773.md) | [0.1](/filings/0001193125-25-264666.md) | [56.7](/filings/0001193125-26-208954.md) | [56.6](/filings/0001193125-26-323773.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 56,435,621 at 2026-07-24, from the cover of the [10-Q filed 2026-07-29](/filings/0001193125-26-323773.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.